A note for UK readers

This page explains Mexico’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.

Does a pharmacy advertisement establish a medicine's approved use?

No. Match the product and presentation to COFEPRIS information, then ask a local clinician about the indication and prescription.

A recorded weight-management indication

COFEPRIS's published biotechnology list includes injectable Wegovy with a weight-management indication for defined patient groups. The entry supports that product's registration history; it is not a live inventory or an assurance that every presentation is stocked.

Payment needs an individual check

The regulatory sources reviewed do not establish a universal public entitlement to GLP-1 obesity treatment. Ask your institution or insurer whether the exact medicine and indication are covered and obtain the applicable requirements in writing.

Authenticity is a practical concern

Mexican health authorities published another falsified Ozempic warning in April 2026. A recognised name on a box is therefore insufficient reassurance. Use a legitimate pharmacy and ask the pharmacist to resolve any concerns about the supplied product.

Keep the UK decision local

Mexican registration and pharmacy prices do not establish UK access or equivalent clinical support. For a UK treatment decision, use a registered UK prescriber and pharmacy, and compare the full GBP care package. This country page is health-system context, not a purchasing route.

Keep these four questions separate

Access

Mexican registration and supply rules only

Funding

No universal funding entitlement verified in this review

Cost context

MXN pricing is not a UK treatment-cost estimate

Regulatory source

COFEPRIS

Compare health systems ↗
Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. COFEPRIS: registered innovative biotechnology medicines
  2. Baja California health authority: COFEPRIS Ozempic alert, April 2026
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →